

October 1, 2013

Notice of Revision of Financial Forecast

Hisamitsu Pharmaceutical Co., Inc., (Head Office: Tosu city, Saga prefecture, Japan; President and CEO: Hirotaka Nakatomi, hereinafter referred to as Hisamitsu) announces, in light of the recent trend in our business performance, as follows, the revision of consolidated financial forecast for the second quarter (cumulative) of the fiscal year ending February 28, 2014, which had been released on April 11, 2013.

1. Revision of Consolidated Financial Forecast for Second Quarter (Cumulative)

Revised Consolidated Financial Forecast for Second Quarter (Cumulative) of Fiscal Year Ending February 28, 2014

(March 1, 2013, through August 31, 2013)

(Amounts in millions of yen, except amounts per share in yen)

	Net Sales	Operating Income	Ordinary Income	Quarterly Net Income	Quarterly Net Income per Share
Previous Forecast (A)	76,800	10,000	13,600	11,500	134.24 yen
Revised Forecast (B)	77,300	12,400	16,800	13,600	158.75 yen
Variance in Amount (B-A)	+ 500	+ 2,400	+ 3,200	+ 2,100	
Variance in Percentage (%)	+ 0.6%	+ 24.0%	+ 23.5%	+ 18.3%	
*Ref. Second Quarter Results of Prior Fiscal Year (Second Quarter of Fiscal Year Ended February 28, 2013)	71,932	13,248	16,481	9,334	108.96 yen

2. Reasons for the Revision

The reason for revising the consolidated financial forecast for second quarter (cumulative) of fiscal year ending February 28, 2014 is that the operating income, ordinary income, and quarterly net income for the said quarter are expected to exceed the figures contained in the previous forecast (A) due to the deferral of the unused research expense and the selling expense (both recorded as selling, general and administrative expenses) by Hisamitsu, non-consolidated, to the third quarter onwards. As a result, the figures were revised as shown in the revised forecast (B).

3. Consolidated Full Year Financial Forecast for Fiscal Year Ending February 28, 2014

At this juncture, there is no change in the consolidated full-year financial forecasts for the fiscal year ending February 28, 2014. Depending on progress in the implementation of measures to promote the sales of our major products, if it becomes necessary for us to revise the consolidated full-year financial forecasts for the fiscal year ending February 28, 2014, we will promptly disclose the revisions.

4. Dividends

At this juncture, there is no change in our plan for the payment of interim and year-end dividends.

* The financial forecasts described above are prepared on the basis of information available as of the date of this announcement. Actual financial results may differ from those included in these financial forecasts due to a variety of factors going forward.